Ropes & Gray represented Blackstone Life Sciences in a collaboration with Teva Pharmaceuticals where funds managed by Blackstone Life Sciences will provide $400 million over four years to support the clinical development of duvakitug, a human monoclonal antibody targeting TL1A, a mediator of inflammation and fibrosis, currently in phase 3 clinical studies for the treatment of ulcerative colitis and Crohn's disease. The transaction was announced on March 3.
Under the agreement, Blackstone will be eligible to receive regulatory and commercial milestones as well as royalties on duvakitug worldwide sales.
The Ropes & Gray team was led by life sciences licensing partner Abigail Gregor and associate James Gould and included IP transactions partner Melissa Rones, IP transactions counsel Ryan Murphey, and life sciences licensing associate Ben Ellington.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.